Top

Published in:

01-05-2014 | Laboratory Investigation

Uptake by human glioma cell lines and biological effects of a peptide-nucleic acids targeting miR-221

Authors: Eleonora Brognara, Enrica Fabbri, Elena Bazzoli, Giulia Montagner, Claudio Ghimenton, Albino Eccher, Cinzia Cantù, Alex Manicardi, Nicoletta Bianchi, Alessia Finotti, Giulia Breveglieri, Monica Borgatti, Roberto Corradini, Valentino Bezzerri, Giulio Cabrini, Roberto Gambari

Published in: Journal of Neuro-Oncology | Issue 1/2014

Abstract

MicroRNAs are a family of small noncoding RNAs regulating gene expression by sequence-selective mRNA targeting, leading to a translational repression or mRNA degradation. The oncomiR miR-221 is highly expressed in human gliomas, as confirmed in this study in samples of low and high grade gliomas, as well in the cell lines U251, U373 and T98G. In order to alter the biological functions of miR-221, a peptide nucleic acid targeting miR-221 (R8-PNA-a221) was produced, bearing a oligoarginine peptide (R8) to facilitate uptake by glioma cells. The effects of R8-PNA-a221 were analyzed in U251, U373 and T98G glioma cells and found to strongly inhibit miR-221. In addition, the effects of R8-PNA-a221 on p27^Kip1 (a target of miR-221) were analyzed in U251 and T98G cells by RT-qPCR and by Western blotting. No change of p27^Kip1 mRNA content occurs in U251 cells in the presence of PNA-a221 (lacking the R8 peptide), whereas significant increase of p27^Kip1 mRNA was observed with the R8-PNA-a221. These data were confirmed by Western blot assay. A clear increment of p27^Kip1 protein expression in the samples treated with R8-PNA-a221 was detected. In addition, R8-PNA-a221 was found able to increase TIMP3 expression (another target of miR-221) in T98G cells. These results suggest that PNAs against oncomiRNA miR-221 might be proposed for experimental treatment of human gliomas.

Available only for authorised users

Nielsen PE, Egholm M, Berg RH, Buchardt O (1991) Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 254:1497–1500PubMedCrossRef

Nielsen PE (2001) Targeting double stranded DNA with peptide nucleic acid (PNA). Curr Med Chem 8:545–550PubMedCrossRef

Borgatti M, Lampronti I, Romanelli A, Pedone C, Saviano M et al (2003) Transcription factor decoy molecules based on a peptide nucleic acid (PNA)-DNA chimera mimicking Sp1 binding sites. J Biol Chem 278:7500–7509PubMedCrossRef

Gambari R (2001) Peptide-nucleic acids (PNAs): a tool for the development of gene expression modifiers. Curr Pharm Des 7:1839–1862PubMedCrossRef

Gambari R (2004) Biological activity and delivery of peptide nucleic acids (PNA)-DNA chimeras for transcription factor decoy (TFD) pharmacotherapy. Curr Med Chem 11:1253–1263PubMedCrossRef

Nielsen PE (2010) Peptide nucleic acids (PNA) in chemical biology and drug discovery. Chem Biodivers 7:786–804PubMedCrossRef

Hatamoto M, Ohashi A, Imachi H (2010) Peptide nucleic acids (PNAs) antisense effect to bacterial growth and their application potentiality in biotechnology. Appl Microbiol Biotechnol 86:397–402PubMedCrossRef

Gambari R, Borgatti M, Bezzerri V, Nicolis E, Lampronti I et al (2010) Decoy oligodeoxyribonucleotides and peptide nucleic acids-DNA chimeras targeting nuclear factor kappa-B: inhibition of IL-8 gene expression in cystic fibrosis cells infected with Pseudomonas aeruginosa. Biochem Pharmacol 80:1887–1894PubMedCrossRef

Pandey VN, Upadhyay A, Chaubey B (2009) Prospects for antisense peptide nucleic acid (PNA) therapies for HIV. Expert Opin Biol Ther 9:975–989PubMedCentralPubMedCrossRef

10.

Nielsen PE (2010) Gene targeting and expression modulation by peptide nucleic acids (PNA). Curr Pharm Des 16:3118–3123PubMedCrossRef

11.

Manicardi A, Fabbri E, Tedeschi T, Sforza S, Bianchi N et al (2012) Cellular Uptakes, biostabilities and anti-miR-210 activities of chiral Arginine-PNAs in leukaemic K562 cells. Chembiochem 13:1327–1337PubMedCentralPubMedCrossRef

12.

Fabbri E, Manicardi A, Tedeschi T, Sforza S, Bianchi N et al (2011) Modulation of the biological activity of microRNA-210 with peptide nucleic acids (PNAs). ChemMedChem 6:2192–2202PubMedCrossRef

13.

Gambari R, Fabbri E, Borgatti M, Lampronti I, Finotti A et al (2011) Targeting microRNAs involved in human diseases: a novel approach for modification of gene expression and drug development. Biochem Pharmacol 82:1416–1429PubMedCrossRef

14.

Fabani MM, Gait MJ (2008) MiR-122 targeting with LNA/2’-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. RNA 14:336–346PubMedCentralPubMedCrossRef

15.

Fabani MM, Abreu-Goodger C, Williams D, Lyons PA, Torres AG et al (2010) Efficient inhibition of miR-155 function in vivo by peptide nucleic acids. Nucleic Acids Res 38:4466–4475PubMedCentralPubMedCrossRef

16.

Brown PN, Yin H (2013) PNA-based microRNA inhibitors elicit anti-inflammatory effects in microglia cells. Chem Commun (Camb) 49:4415–4417CrossRef

17.

Brognara E, Fabbri E, Aimi F, Manicardi A, Bianchi N et al (2012) Peptide nucleic acids targeting miR-221 modulate p27^Kip1 expression in breast cancer MDA-MB-231 cells. Int J Oncol 41:2119–2127PubMed

18.

He L, Hannon GJ (2010) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5:522–531CrossRef

19.

Piva R, Spandidos DA, Gambari R (2013) From microRNA functions to microRNA therapeutics: novel targets and novel drugs in breast cancer research and treatment. Int J Oncol 43:985–994PubMedCentralPubMed

20.

Shah MY, Calin GA (2011) MicroRNAs miR-221 and miR-222: a new level of regulation in aggressive breast cancer. Genome Med 3:56PubMedCentralPubMedCrossRef

21.

Lambertini E, Lolli A, Vezzali F, Penolazzi L, Gambari R, Piva R (2012) Correlation between Slug transcription factor and miR-221 in MDA-MB-231 breast cancer cells. BMC Cancer 12:445PubMedCentralPubMedCrossRef

22.

Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV et al (2007) MiR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 282:2316–2324CrossRef

23.

Zhang C, Zhang J, Hao J, Shi Z, Wang Y et al (2012) High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma. J Transl Med 10:119PubMedCentralPubMedCrossRef

24.

Zhang CZ, Zhang JX, Zhang AL, Shi ZD, Han L et al (2010) MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol Cancer 9:229PubMedCentralPubMedCrossRef

25.

Lakomy R, Sana J, Hankeova S, Fadrus P, Kren L et al (2011) MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. Cancer Sci 102:2186–2190PubMedCrossRef

26.

Le Sage C, Nagel R, Egan DA, Schrier M, Mesman E (2007) Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 26:3699–3708PubMedCentralPubMedCrossRef

27.

Lorimer IA (2009) Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle 8:2685PubMedCrossRef

28.

Bhatia B (2010) On the move: p27Kip1 drives cell motility in glioma cells. Cell Cycle 9:1231–1240PubMedCrossRef

29.

Lu X, Zhao P, Zhang C, Fu Z, Chen Y et al (2009) Analysis of miR-221 and p27 expression in human gliomas. Mol Med Rep 2:651–656PubMed

30.

Gillies JK, Lorimer IA (2007) Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle 6:2005–2009PubMedCrossRef

31.

Ueda R, Kohanbash G, Sasaki K, Fujita M, Zhu X et al (2009) Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. Proc Natl Acad Sci USA 106:10746–10751PubMedCentralPubMedCrossRef

32.

Zerrouqi A, Pyrzynska B, Febbraio M, Brat DJ, Van Meir EG (2012) P14ARF inhibits human glioblastoma-induced angiogenesis by upregulating the expression of TIMP3. J Clin Invest 122:1283–1295PubMedCentralPubMedCrossRef

33.

Wang Y, Wang X, Zhang J, Sun G, Luo H et al (2012) MicroRNAs involved in the EGFR/PTEN/AKT pathway in gliomas. J Neurooncol 106:217–224PubMedCrossRef

34.

Zhang C, Kang C, You Y, Pu P, Yang W (2009) Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27Kip1 in vitro and in vivo. Int J Oncol 34:1653–1660PubMedCrossRef

35.

Schiappacassi M, Lovat F, Canzonieri V, Belletti B, Berton S et al (2008) p27Kip1 expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis. Mol Cancer Ther 7:1164–1175PubMedCrossRef

36.

Tabu K, Ohnishi A, Sunden Y, Suzuki T, Tsuda M et al (2006) A novel function of OLIG2 to suppress human glial tumor cell growth via p27Kip1 transactivation. J Cell Sci 119:1433–1441PubMedCrossRef

37.

Cao X, Gu Y, Jiang L, Wang Y, Liu F et al (2013) A new approach to screening cancer stem cells from the U251 human glioma cell line based on cell growth state. Oncol Rep 29:1013–1018PubMed

38.

Abdullah NA, Sallis B, Nuttall R, Schubert FR, Ahsan M et al (2012) Induction of apoptosis and reduction of MMP gene expression in the U373 cell line by polyphenolics in Aronia melanocarpa and by curcumin. Oncol Rep 28:1435–1442

39.

Pen A, Durocher Y, Slinn J, Rukhlova M, Charlebois C et al (2011) Insulin-like growth factor binding protein 7 exhibits tumor suppressive and vessel stabilization properties in U87MG and T98G glioblastoma cell lines. Cancer Biol Ther 12:634–646PubMedCrossRef

40.

Abes R, Arzumanov A, Moulton H, Abes S, Ivanova G (2008) Arginine-rich cell penetrating peptides: design, structure–activity, and applications to alter pre-mRNA splicing by steric-block oligonucleotides. J Pept Sci 14:455–460PubMedCrossRef

41.

Jensen KK, Orum H, Nielsen PE, Nordén B (1997) Kinetics for hybridization of peptide nucleic acids (PNA) with DNA and RNA studied with the BIAcore technique. Biochemistry 36:5072–5077PubMedCrossRef

42.

Corradini R, Feriotto G, Sforza S, Marchelli R, Gambari R (2004) Enhanced recognition of cystic fibrosis W1282X DNA point mutation by chiral peptide nucleic acid probes by a surface plasmon resonance biosensor. J Mol Recognit 17:76–84PubMedCrossRef

43.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109PubMedCentralPubMedCrossRef

44.

Hermansen SK, Kristensen BW (2013) MicroRNA biomarkers in glioblastoma. J Neurooncol 114:13–23PubMedCrossRef

45.

Rothbard JB, Kreider E, Van Deusen CL, Wright L, Wylie BL (2002) Arginine-rich molecular transporters for drug delivery: role of backbone spacing in cellular uptake. J Med Chem 45:3612–3618PubMedCrossRef

46.

Qian X, Ren Y, Shi Z, Long L, Pu P et al (2012) Sequence-dependent synergistic inhibition of human glioma cell lines by combined temozolomide and miR-21 inhibitor gene therapy. Mol Pharm 9:2636–2645PubMedCrossRef

47.

Chen L, Zhang J, Han L, Zhang A, Zhang C et al (2012) Down regulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status. Oncol Rep 27:854–860PubMed

48.

Suzuki T, Wu D, Schlachetzki F, Li JY, Boado RJ (2004) Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. J Nucl Med 45:1766–1775PubMed

49.

Boado RJ, Tsukamoto H, Pardridge WM (1998) Drug delivery of antisense molecules to the brain for treatment of Alzheimer’s disease and cerebral AIDS. J Pharm Sci 87:1308–1315PubMedCrossRef

50.

Sethi D, Chen CP, Jing RY, Thakur ML, Wickstrom E (2012) Fluorescent peptide-PNA chimeras for imaging monoamine oxidase A mRNA in neuronal cells. Bioconjug Chem 23:158–163PubMedCentralPubMedCrossRef

Title: Uptake by human glioma cell lines and biological effects of a peptide-nucleic acids targeting miR-221
Authors: Eleonora Brognara
Enrica Fabbri
Elena Bazzoli
Giulia Montagner
Claudio Ghimenton
Albino Eccher
Cinzia Cantù
Alex Manicardi
Nicoletta Bianchi
Alessia Finotti
Giulia Breveglieri
Monica Borgatti
Roberto Corradini
Valentino Bezzerri
Giulio Cabrini
Roberto Gambari
Publication date: 01-05-2014
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2014
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-014-1405-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Uptake by human glioma cell lines and biological effects of a peptide-nucleic acids targeting miR-221

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Stereotactic radiosurgery for cavernous sinus hemangiomas

Mouse models of glioblastoma: lessons learned and questions to be answered

Visual outcome after fractionated stereotactic radiation therapy of benign anterior skull base tumors

Heat shock protein 47 regulated by miR-29a to enhance glioma tumor growth and invasion

Activation of ErbB2- ErbB3 signaling pathway supports potential therapeutic activity of ErbB inhibitors in AT/RT

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases